Molecular Therapeutics

分子治疗学

• 批准号: 10553187
• 负责人: Asfar S Azmi
• 金额: $ 4.62万
• 依托单位: WAYNE STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-08 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10553187
• 关键词: African American; African American population; Anatomy; Benchmarking; Biological; Biological Markers; Cancer Center; Cancer Center Support Grant; Catchment Area; Classification; Clinic; Clinical; Clinical Drug Development; Clinical Investigator; Clinical Trials; Clinical effectiveness; Collaborations; Communities; Conduct Clinical Trials; Disparity; Dose; Drug Combinations; Drug Design; Enrollment; Family; Funding; Genetic; Genetic Transcription; Genomics; Goals; Immunologic Markers; Incidence; Industry; Institution; International; Intervention; Laboratories; Laboratory Finding; Lead; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of prostate; Manuscripts; Michigan; Minority Groups; Mission; Molecular; NCI Center for Cancer Research; New Agents; Nuclear; Pathway interactions; Patients; Peer Review; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Phase II Clinical Trials; Population Study; Prediction of Response to Therapy; Process; Publishing; Research; Research Personnel; Research Project Grants; Schools; Scientist; Signal Pathway; Stromal Cells; Stromal Neoplasm; Testing; Therapeutic; Therapeutic Agents; Toxic effect; Traditional Medicine; Translating; Tumor Biology; Tumor Markers; Tumor-infiltrating immune cells; Universities; Work; base; cancer health disparity; cancer therapy; cancer type; chemotherapy; clinical translation; clinical trial enrollment; clinically relevant; drug development; drug discovery; early phase trial; effectiveness validation; follow-up; genomic biomarker; high throughput screening; improved; interest; malignant breast neoplasm; member; molecular imaging; molecular marker; multidisciplinary; novel; novel strategies; novel therapeutic intervention; novel therapeutics; patient oriented; personalized medicine; pharmacodynamic biomarker; pharmacokinetics and pharmacodynamics; phase 2 study; phase II trial; phase III trial; programs; psychosocial; racial difference; response; small molecule libraries; structural biology; translational cancer research; translational study; treatment response; treatment trial; tumor; tumor metabolism; tumor microenvironment

MOLECULAR THERAPEUTICS – ABSTRACT The mission of the Molecular Therapeutics (MT) Program is to translate laboratory findings to the clinic and to facilitate collaborations between basic and clinical scientists, to improve the lives of patients with cancer by identifying new molecules, targets, and strategies for treating cancer. This highly interactive Program includes 50 members from 11 departments and 4 schools at Wayne State University and the Karmanos Cancer Institute (KCI) Network and $3,031,514 in peer reviewed, cancer-related funding, of which $971,206 is from the NCI. Additionally, industry-sponsored clinical trial funding is $29,599,781. Program membership includes a cross section of laboratory-based and clinical investigators in the KCI who interact through programmatic activities and collaborate on research grants and investigator-initiated clinical trials. The scientific themes of the MT Program are to: 1) identify and validate novel therapeutics, targets and pathways for selective tumor targeting; 2) identify cellular/molecular determinants and biomarkers of tumor response; and 3) validate effectiveness of new agents in interventional treatment trials. The MT Program focuses on new approaches for treating cancer, ranging from drug discovery to mechanism-based efforts emphasizing mechanisms-of-action of novel tumor-targeted and standard agents and critical signaling pathways, all with the goal of clinical translation. The interests of MT members include tumor metabolism, nuclear transporters, transcriptional targets, and signaling pathways, and extend to the impact of therapy on tumor-infiltrating immune cells. Biomarker research includes pharmacokinetics and pharmacodynamics, cellular and molecular biomarkers and molecular/genetic profiles predictive of responses to therapy and/or that lead to actionable therapies. A particular emphasis is on biomarkers relevant to cancer disparities between African American and white patients as treatment targets and for personalized treatment trials. Research in the MT Program draws from our nationally/internationally recognized clinical trials program at KCI, which employs tumor profiling (including genomic profiling) to facilitate enrollment on phase I and early phase II trials and to identify patients most likely to respond to particular treatments. Phase II clinical trials draw from basic laboratory findings, culminating in investigator-initiated clinical trials. MT members lead phase III trials, often working with multi-center teams and cooperative groups. MT Program members study all major cancer types including those that occur at high incidence in the KCI catchment area. These initiatives have helped define cancer health disparities in our catchment area, identify racial differences in tumor biology, and led to enrollment of large numbers of African Americans in clinical trials. The overriding goal of the MT Program is to conduct and deliver patient-centered cancer research and treatment to benefit patients in the catchment area. MT Program members extensively collaborate with members of the MI, TBM, and PSDR Programs at KCI. Of the 935 manuscripts published between December 2015 and November 2019, 34% and 32% were intra- and inter-programmatic, respectively, and 62% were multi-institutional collaborations.

分子治疗学-摘要 分子治疗(MT)计划的任务是将实验室结果转化为临床和 促进基础和临床科学家之间的合作，通过以下方式改善癌症患者的生活 确定治疗癌症的新分子、靶点和策略。这一高度互动的计划包括 来自韦恩州立大学和卡马诺斯癌症研究所11个系和4个学院的50名成员 KCI网络和3 031 514美元的同行评议的癌症相关资金，其中971 206美元来自NCI。 此外，行业赞助的临床试验资金为29,599,781美元。计划成员资格包括一个十字 KCI的实验室和临床调查员部门，他们通过方案活动和 就研究资助和研究人员发起的临床试验进行合作。翻译计划的科学主题 是：1)识别和验证用于选择性肿瘤靶向的新疗法、靶点和途径；2)识别 肿瘤反应的细胞/分子决定因素和生物标志物；以及3)验证新药物的有效性 在介入治疗试验中。MT计划专注于治疗癌症的新方法，范围从 药物发现到以机制为基础的努力，强调新的肿瘤靶向和 标准代理和关键信号通路，所有这些都以临床翻译为目标。MT的利益 成员包括肿瘤代谢、核转运体、转录靶点和信号通路，以及 延伸到治疗对肿瘤浸润性免疫细胞的影响。生物标记物研究包括药代动力学 和药效学，细胞和分子生物标志物和分子/遗传图谱预测 对治疗的反应和/或导致可操作的治疗。特别强调的是相关的生物标志物。 将非裔美国人和白人患者之间的癌症差异作为治疗目标并进行个性化 治疗试验。MT计划的研究借鉴了我们国家/国际公认的临床试验 KCI计划，该计划使用肿瘤简档(包括基因组简档)来促进第一阶段的登记 和早期II期试验，并确定最有可能对特定治疗有反应的患者。II期临床 试验从基本的实验室结果中得出，最终由研究人员发起临床试验。MT成员领先 第三阶段试验，通常与多中心团队和合作小组合作。MT计划成员学习所有 主要癌症类型，包括在KCI集水区高发的癌症。这些倡议已经 帮助定义了我们集水区的癌症健康差异，确定了肿瘤生物学中的种族差异，以及 导致大量非裔美国人参加临床试验。机器翻译计划的首要目标 是进行和提供以患者为中心的癌症研究和治疗，以造福集水区的患者 区域。MT计划成员与MI、TBM和PSDR计划成员广泛协作，地址为 KCI。在2015年12月至2019年11月发表的935篇稿件中，34%和32%是内部稿件。 和方案间合作，62%是多机构合作。